A generics powerhouse worth some $20 billion in revenues is to be created by the merger of Netherlands-incorporated Mylan (Nasdaq: MYL) and the off-patent business of New York-based pharma giant Pfizer (NYSE: PFE).
Pfizer’s Upjohn unit, which promotes aging thoroughbreds such as Lipitor (atorvastatin) and Viagra (sildenafil), will complement Mylan’s portfolio of new generics and biosimilars.
The combined entity will enjoy an expanded global reach, with strong positions in China and other emerging markets, and will benefit from the synergy of Mylan’s R&D-focused pipeline, and Upjohn’s commercial and medical infrastructure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze